Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday.
Related Articles
Debunking the “dumb superintelligence” myth | Dr. Melanie Mitchell
We created this video in partnership with @AbundanceInstitute AI expert Dr. Melanie Mitchell breaks down what “intelligence” really means – and why our fears…
Speech Data Annotation Technology in Self-driving cars
Speech data annotation plays a crucial role in the development of self-driving cars that interact with the vehicle through voice commands.
Online Event
In the realm of rare disease research, collaboration across disciplines, organization types, and disease types is essential to accelerating progress. Traditionally, scientists have focused on…
Compass Pathways’ depression drug succeeds late-stage trial
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.
Multimodal information structuring with single-layer soft skins and high-density electrical impedance tomography
High-density impedance measurements were used to monitor multimodal stimuli from single-layer skins over a hollow 3D hand.
Videos of bat-munching animals may show how viruses spread
People without protective gear also visit cave where bats with deadly virus likely reside
Funding cuts to U.S. archaeology could imperil field’s future
A Science analysis of canceled and curtailed federal grants reveals hits to research, collections, and training
A spatially organized Cd24a+/Pax9+ stem cell core governs postnatal tooth establishment
A conserved and spatially organized Cd24a+/Pax9+ core governs postnatal tooth establishment, guided by PDGFB from alveolar bone.
Sharks may use an unexpected organ to fight microbial invaders
The pancreas, which helps control blood sugar in humans, may be critical part of shark immune system
Writing in the Age of Shared Authorship
In the age of AI, authorship isn’t lost, it’s shared. And that changes everything.